Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Relay Therapeutics (RLAY)
NASDAQ:RLAY
Holding RLAY?
Track your performance easily
RLAY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.70 - $12.14
Previous Close$7.6
Volume1.48M
Average Volume (3M)1.88M
Market Cap
$1.23B
Enterprise Value$1.15B
Total Cash (Recent Filing)$134.13M
Total Debt (Recent Filing)$51.10M
Price to Earnings (P/E)―
Beta2.47
Next Earnings
Oct 31, 2024EPS Estimate
-$0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.52
Shares Outstanding133,889,966
10 Day Avg. Volume5,815,769
30 Day Avg. Volume1,882,509
Standard Deviation0.19
R-Squared0.18
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)1.55
Price to Sales (P/S)28.90
Price to Cash Flow (P/CF)-3.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue32.71
Enterprise Value/Gross Profit45.08
Enterprise Value/Ebitda-4.65
Forecast
1Y Price Target
$20.56Price Target Upside171.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Relay Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsOverall, today’s data position RLY-2608 for best-in-class profile on both efficacy and safety relative to competitions.
Efficacy And SafetyRLY-2608 looks safe and well tolerated compared to competing AKT/PIK3CA-targeting agents, including 25% grade-3 treatment related adverse events (AE) from RLY-2608 vs. 33-62% from competitors.
Market PerformanceThe stock was up ~52% on the news, based on the drug's long durability, with a mPFS of 9.2 months for the doublet.
Bears Say
Clinical Trial ResultsUpdated results from ReDiscover revealed a clinical benefit rate of 57%, which falls short of higher expectations.
Competitor AdvantageCompetitors like Scorpion and OnKure have more selective drugs, posing a significant challenge.
Partnership TerminationRoche terminated its collaboration agreement for the SHP2 inhibitor RLY-1971, ending all future milestone payments.
---
Ownership Overview
Currently, No data available
---
RLAY FAQ
What was Relay Therapeutics’s price range in the past 12 months?
Relay Therapeutics lowest stock price was $5.70 and its highest was $12.14 in the past 12 months.
What is Relay Therapeutics’s market cap?
Currently, no data Available
When is Relay Therapeutics’s upcoming earnings report date?
Relay Therapeutics’s upcoming earnings report date is Oct 31, 2024 which is in 42 days.
How were Relay Therapeutics’s earnings last quarter?
Relay Therapeutics released its earnings results on Aug 06, 2024. The company reported -$0.69 earnings per share for the quarter, beating the consensus estimate of -$0.733 by $0.043.
Is Relay Therapeutics overvalued?
According to Wall Street analysts Relay Therapeutics’s price is currently Undervalued.
Does Relay Therapeutics pay dividends?
Relay Therapeutics does not currently pay dividends.
What is Relay Therapeutics’s EPS estimate?
Relay Therapeutics’s EPS estimate is -$0.77.
How many shares outstanding does Relay Therapeutics have?
Relay Therapeutics has 162,461,400 shares outstanding.
What happened to Relay Therapeutics’s price movement after its last earnings report?
Relay Therapeutics reported an EPS of -$0.69 in its last earnings report, beating expectations of -$0.733. Following the earnings report the stock price went down -7.928%.
Which hedge fund is a major shareholder of Relay Therapeutics?
Among the largest hedge funds holding Relay Therapeutics’s share is Baker Bros Advisors LP. It holds Relay Therapeutics’s shares valued at 8M.
---
Relay Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.56 (171.24% Upside)
$20.56 (171.24% Upside)
Blogger Sentiment
Bullish
RLAY Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 276.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $74.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 13.1%
Last 30 Days ▲ 11.0%
Last 30 Days ▲ 11.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.89%
12-Months-Change
Fundamentals
Return on Equity
-43.28%
Trailing 12-Months
Asset Growth
-19.69%
Trailing 12-Months
Company Description
Relay Therapeutics
Relay Therapeutics Inc is a precision medicines company focused on enhancing small molecule therapeutic discovery in targeted oncology. Its pipeline products include RLY-1971 and RLY-4008 and among others.
---
RLAY Stock 12 Month Forecast
Average Price Target
$20.56
▲(171.24% Upside)
Technical Analysis
Best Analysts Covering RLAY
1 Year
1 Year Success Rate
3/10 ratings generated profit
1 Year Average Return
-19.01%
reiterated a buy rating 11 days ago
Copying Jason Gerberry's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -19.01% per trade.
---